Eli Lilly Completes $2.9 Billion Biotech Acquisition

Pharmaceutical giant Eli Lilly has finalized the acquisition of another biotech company for $2.9 billion. This substantial investment aligns with Eli Lilly's ongoing strategy to expand into new markets and strengthen its portfolio. The move underscores the company's commitment to growth through strategic mergers and acquisitions in the biotechnology sector.